Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 1
1995 2
1997 2
1998 2
1999 4
2001 1
2002 7
2003 3
2004 3
2005 3
2006 4
2007 7
2008 7
2009 9
2010 7
2011 4
2012 4
2013 4
2014 5
2015 8
2016 6
2017 1
2018 1
2019 2
2020 1
2021 2
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: 1Starting
Page 1
Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains.
Cilento ME, Reeve AB, Michailidis E, Ilina TV, Nagy E, Mitsuya H, Parniak MA, Tedbury PR, Sarafianos SG. Cilento ME, et al. Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0116721. doi: 10.1128/AAC.01167-21. Epub 2021 Sep 13. Antimicrob Agents Chemother. 2021. PMID: 34516245 Free PMC article. Clinical Trial.
4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA, MK-8591, islatravir) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) with exceptional potency against wild-type (WT) and drug-resistant HIV-1 in phase III clinical trials. ...Remarkably …
4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA, MK-8591, islatravir) is a nucleoside reverse transcriptase translocation inhibitor (NRTT …
Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.
Feng M, Sachs NA, Xu M, Grobler J, Blair W, Hazuda DJ, Miller MD, Lai MT. Feng M, et al. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2241-7. doi: 10.1128/AAC.02650-15. Print 2016 Apr. Antimicrob Agents Chemother. 2016. PMID: 26833152 Free PMC article.
Doravirine (DOR), which is currently in a phase 3 clinical trial, is a novel human immunodeficiency type 1 virus (HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI). DOR exhibits potent antiviral activity against wild-type …
Doravirine (DOR), which is currently in a phase 3 clinical trial, is a novel human immunodeficiency type 1 virus …
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
Underwood M, Horton J, Nangle K, Hopking J, Smith K, Aboud M, Wynne B, Sievers J, Stewart EL, Wang R. Underwood M, et al. Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0164321. doi: 10.1128/AAC.01643-21. Epub 2021 Oct 25. Antimicrob Agents Chemother. 2022. PMID: 34694877 Free PMC article. Clinical Trial.
At week 48 in the phase IIIb DAWNING study, the integrase strand transfer inhibitor (INSTI) dolutegravir plus 2 nucleoside reverse transcriptase inhibitors demonstrated superiority to ritonavir-boosted lopinavir in achieving virologic suppression in adults with HIV- …
At week 48 in the phase IIIb DAWNING study, the integrase strand transfer inhibitor (INSTI) dolutegravir plus 2 nucleoside reverse tr …
Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).
Diamond TL, Ngo W, Xu M, Goh SL, Rodriguez S, Lai MT, Asante-Appiah E, Grobler JA. Diamond TL, et al. Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0013322. doi: 10.1128/aac.00133-22. Epub 2022 May 12. Antimicrob Agents Chemother. 2022. PMID: 35546110 Free PMC article.
Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) that inhibits human immunodeficiency virus (HIV) reverse transcription by blocking reverse transcriptase (RT) translocation on the primer:template. ISL is bei …
Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) that inhibits human immunodeficiency …
Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.
Sale M, Sadler BM, Stein DS. Sale M, et al. Antimicrob Agents Chemother. 2002 Mar;46(3):746-54. doi: 10.1128/AAC.46.3.746-754.2002. Antimicrob Agents Chemother. 2002. PMID: 11850257 Free PMC article. Clinical Trial.
Simulated minimum amprenavir concentrations in plasma (Cmin) in twice-daily and once-daily dosing regimens were compared with protein binding-adjusted 50% inhibitory concentrations (IC50s) for clinical human immunodeficiency virus isolates with different susc …
Simulated minimum amprenavir concentrations in plasma (Cmin) in twice-daily and once-daily dosing regimens were compared with protein bindin …
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
Asif G, Hurwitz SJ, Obikhod A, Delinsky D, Narayanasamy J, Chu CK, McClure HM, Schinazi RF. Asif G, et al. Antimicrob Agents Chemother. 2007 Jul;51(7):2424-9. doi: 10.1128/AAC.01498-06. Epub 2007 May 7. Antimicrob Agents Chemother. 2007. PMID: 17485498 Free PMC article.
Beta-D-dioxolane-thymine (D-DOT) has potent and selective in vitro activity against several clinically important resistant human immunodeficiency virus (HIV) mutants and is in advanced preclinical development. ...D-DOT reached levels in the cere …
Beta-D-dioxolane-thymine (D-DOT) has potent and selective in vitro activity against several clinically important resistant human i …
Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.
Vourvahis M, Langdon G, Labadie RR, Layton G, Ndongo MN, Banerjee S, Davis J. Vourvahis M, et al. Antimicrob Agents Chemother. 2012 Feb;56(2):887-92. doi: 10.1128/AAC.00572-11. Epub 2011 Nov 28. Antimicrob Agents Chemother. 2012. PMID: 22123705 Free PMC article. Clinical Trial.
Lersivirine (UK-453,061) is a new nonnucleoside reverse transcriptase inhibitor currently being developed as a treatment for human immunodeficiency virus type 1 infection. Lersivirine shows potent activity against wild-type and cli …
Lersivirine (UK-453,061) is a new nonnucleoside reverse transcriptase inhibitor currently being developed as a treatment for human …
Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.
Yoshinaga T, Kobayashi M, Seki T, Miki S, Wakasa-Morimoto C, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T. Yoshinaga T, et al. Antimicrob Agents Chemother. 2015 Jan;59(1):397-406. doi: 10.1128/AAC.03909-14. Epub 2014 Nov 3. Antimicrob Agents Chemother. 2015. PMID: 25367908 Free PMC article.
The protein-adjusted half-maximal inhibitory concentration (PA-EC50) extrapolated to 100% human serum was 102 nM. When the virus was passaged in the presence of GSK1265744, highly resistant mutants with more than a 10-fold change (FC) in EC50 relative to that of the …
The protein-adjusted half-maximal inhibitory concentration (PA-EC50) extrapolated to 100% human serum was 102 nM. When the virus …
Nucleocapsid Protein Precursors NCp9 and NCp15 Suppress ATP-Mediated Rescue of AZT-Terminated Primers by HIV-1 Reverse Transcriptase.
Árquez MA, Martín-Alonso S, Gorelick RJ, Scott WA, Acosta-Hoyos AJ, Menéndez-Arias L. Árquez MA, et al. Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00958-20. doi: 10.1128/AAC.00958-20. Print 2020 Sep 21. Antimicrob Agents Chemother. 2020. PMID: 32747359 Free PMC article.
In HIV-1, development of resistance to AZT (3'-azido-3'-deoxythymidine) is mediated by the acquisition of thymidine analogue resistance mutations (TAMs) (i.e., M41L, D67N, K70R, L210W, T215F/Y, and K219E/Q) in the viral reverse transcriptase (RT). ...NC proteins int …
In HIV-1, development of resistance to AZT (3'-azido-3'-deoxythymidine) is mediated by the acquisition of thymidine analogue r …
In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.
Lai MT, Feng M, Falgueyret JP, Tawa P, Witmer M, DiStefano D, Li Y, Burch J, Sachs N, Lu M, Cauchon E, Campeau LC, Grobler J, Yan Y, Ducharme Y, Côté B, Asante-Appiah E, Hazuda DJ, Miller MD. Lai MT, et al. Antimicrob Agents Chemother. 2014;58(3):1652-63. doi: 10.1128/AAC.02403-13. Epub 2013 Dec 30. Antimicrob Agents Chemother. 2014. PMID: 24379202 Free PMC article.
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are a mainstay of therapy for treating human immunodeficiency type 1 virus (HIV-1)-infected patients. MK-1439 is a novel NNRTI with a 50% inhibitory concentration (IC50) of 12, 9.7, and 9.7 …
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are a mainstay of therapy for treating human immunodeficiency type …
88 results